STATE-OF-THE-INDUSTRY VIDEOS BY LEADING UROLOGY EXPERTS
Prolonging Time to Metastatic Disease, The SPARTAN Study - Matthew Smith
Matthew Smith
In this conversation with Alicia Morgans, Matthew Smith shares highlights from his 2019 European Society for Medical Oncology annual meeting, (ESMO) presentation.
Cabazitaxel is a New Standard of Care for Third Line Metastatic Prostate Cancer - Bertrand Tombal
Bertrand Tombal
Bertrand Tombal presents the recently published results from the CARD trial: "CARD: A randomized phase 4 trial comparing cabazitaxel and an androgen receptor (AR)-targeted agent in men with metastatic castration-resistant prostate cancer (mCRPC) progressing after docetaxel and an alternative AR-targeted agent".